Why the Stock Market Is a Terrible Thermometer of Biotech Success
In this Backstage Pass segment, recorded on Feb. 4, Motley Fool contributor Rachel Warren discusses the psychedelic therapeutics market with Tim Schlidt, co-founder and partner at Palo Santo, a psychedelic investment fund. Schlidt explains that clinical milestones are the best way to gauge the health of this market going forward.
Source Fool.com